UltraSight Raises $24 Million to Scale AI-Guided Cardiac Workflow Platform Across U.S.
UltraSight, a leader in AI-guided cardiac workflows with its Echosystem platform, has raised $24 million in Series B2 financing to support commercial expansion in the United States. Led by Alive HealthTech Growth Fund, the proceeds will also be used to develop new high-value workflows for intensive care unit and circulatory support settings, where time-critical imaging decisions directly shape patient management, and to support strategic collaborations to expand adoption of the Echosystem product line as it integrates proprietary AI innovations across time-critical cardiac care pathways.
Deep Insight, Star51 Capital, Connecticut Innovations, and eHealth Ventures participated in the financing. Existing investors Mayo Clinic Ventures, NYU, and Iron Nation also participated. The UltraSight Board of Directors will welcome Dudi Klein, Alive co-founder and managing partner; Tal Wenderow, founding managing partner of Star51 Capital; and Barak Ben-Eliezer, managing partner at Deep Insight.
Today, the UltraSight Echosystem is deployed across more than 10 commercial sites spanning intensive care settings, demonstrating growing integration into real-world clinical workflows. A new study published in JAMA Cardiology found that novice operators using AI-guided cardiac ultrasound could acquire high-quality images for automated detection of moderate or greater aortic stenosis, with 93% sensitivity and 96% specificity. The findings highlight the potential of AI-guided ultrasound to expand access to cardiac screening in diverse care settings.
Davidi Vortman, CEO and Co-Founder of UltraSight, stated that when the company is entering its next stage as its FDA-cleared portfolio continues to expand to support broader cardiac imaging workflows, the financing will help translate that momentum into wider market adoption, deeper strategic collaborations, and greater access to high-quality cardiac ultrasound, expediting care for patients who cannot afford to wait.
Dudi Klein, Alive Co-Founder and Managing Partner, said UltraSight combines clinical evidence with a scalable commercial model in a market constrained by access and workforce shortages. Klein noted that the company has developed technology, leadership, and strategic collaborations that position it to support the evolution of cardiac workflows across care settings.
Professor Rafi Beyar, Interventional Cardiologist and General Partner at Alive, said UltraSight has the potential to transform how imaging supports diagnosis and treatment in structural heart disease, where real-time access to high-quality cardiac ultrasound remains critical.
Rick Geoffrion, recently appointed as Chairman of the UltraSight Board, brings more than 30 years of cardiovascular device experience spanning interventional cardiology, circulatory support, structural heart, and commercialization. Geoffrion noted that UltraSight is working to address an unmet need that has constrained the scale-up of advancements in cardiac care for the last 20 years, as current access to reliable ultrasound imaging for diagnosis and treatment remains dependent on a scarce group of experts. Geoffrion added that the financing positions UltraSight to scale that foundation and extend the impact of its AI-guided cardiac workflow platform across cardiovascular care.
